Study finds mechanism to heal injured nerve fibers: Study

Image
ANI
Last Updated : Aug 24 2019 | 3:40 PM IST

Researchers found new mechanisms that enable the regeneration of nerve fibers, which could open up new treatment approaches for the brain, optic nerve, and spinal cord injuries.

The researchers report on these results was published in the journal Nature Communications Biology on 23 August 2019.

The brain, spinal cord, and optic nerves are referred to collectively as the central nervous system. The nerve fibers, called axons, are unable to grow back following injury, meaning that damage is permanent.

"It is possible to partially restore the regenerative capacity of nerve cells in the central nervous system by eliminating the inhibiting protein PTEN. However, a knockout of this kind also triggers many different reactions in the cells at the same time, which often lead to cancer," explained Professor from the Department of Cell Physiology at Ruhr-Universitat Bochum (RUB) Dietmar Fischer.

As a result, the direct inhibition of this protein is not suitable for therapeutic approaches in humans. What's more, the originally postulated mechanism underlying the renewed regenerative capacity following PTEN knockout could not be confirmed in further studies, causing the researchers to seek alternative explanations.

While investigating this as-yet unclear mechanism, the Bochum-based researchers were able to show for the first time that PTEN knockout significantly inhibits an enzyme called glycogen synthase kinase 3, GSK3 for short.

This enzyme, in turn, blocked another protein called collapsin response mediator protein 2, CRMP2.

This meant that the PTEN knockout prevents CRMP2 from being inhibited by GSK3.

"If we directly prevent this second step, i.e., stop the inhibition of CRMP2, we can also achieve the regeneration-promoting effect in a more specific manner," explained Dietmar Fischer.

The activation of CRMP2 itself is not known to have any carcinogenic effect.

"Although we have so far only shown these effects in genetically modified mice and using gene therapy approaches, these findings open up various possibilities for the development of new drug approaches," explained the neuropharmacologist Dietmar Fischer.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 24 2019 | 3:15 PM IST

Next Story